scholarly journals Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease

Brain ◽  
2016 ◽  
Vol 139 (5) ◽  
pp. 1551-1567 ◽  
Author(s):  
Rik Ossenkoppele ◽  
Daniel R. Schonhaut ◽  
Michael Schöll ◽  
Samuel N. Lockhart ◽  
Nagehan Ayakta ◽  
...  
2017 ◽  
Vol 23 (7) ◽  
pp. 1666-1673 ◽  
Author(s):  
K Chiotis ◽  
L Saint-Aubert ◽  
E Rodriguez-Vieitez ◽  
A Leuzy ◽  
O Almkvist ◽  
...  

2021 ◽  
Author(s):  
Niklas Mattsson-Carlgren ◽  
Shorena Janelidze ◽  
Randall Bateman ◽  
Ruben Smith ◽  
Erik Stomrud ◽  
...  

Abstract Alzheimer’s disease is characterized by β-amyloid plaques and tau tangles. Plasma levels of phospho-tau217 (P-tau217) accurately differentiate Alzheimer’s disease dementia from other dementias, but it is unclear to what degree this reflects β-amyloid plaque accumulation, tau tangle accumulation, or both. In a cohort with post-mortem neuropathological data (N=88), both plaque and tangle density contributed independently to higher P-tau217. Several findings were replicated in a cohort with PET imaging (“BioFINDER-2”, N=426), where β-amyloid and tau PET were independently associated to P-tau217. P-tau217 correlated with β-amyloid PET (but not tau PET) in early disease stages, and with both β-amyloid and (more strongly) tau PET in late disease stages. Finally, P-tau217 mediated the association between β-amyloid and tau in both cohorts, especially for tau outside of the medial temporal lobe. These findings support the hypothesis that plasma P-tau217 is increased by both β-amyloid plaques and tau tangles and is congruent with the hypothesis that P-tau is involved in β-amyloid-dependent formation of neocortical tau tangles.


2019 ◽  
Vol 15 (4) ◽  
pp. 570-580 ◽  
Author(s):  
Niklas Mattsson ◽  
Philip S. Insel ◽  
Michael Donohue ◽  
Jonas Jögi ◽  
Rik Ossenkoppele ◽  
...  

2019 ◽  
Vol 15 ◽  
pp. P562-P563
Author(s):  
Antoinette O'Connor ◽  
Pawel J. Markiewicz ◽  
David M. Cash ◽  
Michael Schöll ◽  
Philip SJ. Weston ◽  
...  

2006 ◽  
Vol 14 (7S_Part_3) ◽  
pp. P179-P179 ◽  
Author(s):  
Andrew Stephens ◽  
John Seibyl ◽  
Andre Mueller ◽  
Olivier Barret ◽  
Mathias Berndt ◽  
...  

2020 ◽  
Vol 6 (16) ◽  
pp. eaaz2387 ◽  
Author(s):  
Niklas Mattsson-Carlgren ◽  
Emelie Andersson ◽  
Shorena Janelidze ◽  
Rik Ossenkoppele ◽  
Philip Insel ◽  
...  

The links between β-amyloid (Aβ) and tau in Alzheimer’s disease are unclear. Cognitively unimpaired persons with signs of Aβ pathology had increased cerebrospinal fluid (CSF) phosphorylated tau (P-tau181 and P-tau217) and total-tau (T-tau), which increased over time, despite no detection of insoluble tau aggregates [normal Tau positron emission tomography (PET)]. CSF P-tau and T-tau started to increase before the threshold for Amyloid PET positivity, while Tau PET started to increase after Amyloid PET positivity. Effects of Amyloid PET on Tau PET were mediated by CSF P-tau, and high CSF P-tau predicted increased Tau PET rates. Individuals with MAPT mutations and signs of tau deposition (but without Aβ pathology) had normal CSF P-tau levels. In 5xFAD mice, CSF tau increased when Aβ aggregation started. These results show that Aβ pathology may induce changes in soluble tau release and phosphorylation, which is followed by tau aggregation several years later in humans.


2016 ◽  
Vol 12 ◽  
pp. P145-P145
Author(s):  
Jennifer L. Whitwell ◽  
Keith A. Josephs ◽  
Nirubol Tosakulwong ◽  
Stephen D. Weigand ◽  
Matthew L. Senjem ◽  
...  

2006 ◽  
Vol 14 (7S_Part_2) ◽  
pp. P92-P93
Author(s):  
Shannon L. Risacher ◽  
Eileen F. Tallman ◽  
Darrell WuDunn ◽  
John D. West ◽  
Liana G. Apostolova ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document